Alle Storys
Folgen
Keine Story von CHRIST WATER TECHNOLOGY AG mehr verpassen.

CHRIST WATER TECHNOLOGY AG

euro adhoc: CHRIST WATER TECHNOLOGY AG
quarterly or semiannual financial statement
PRO-FORMA INTERIM GROUP REPORT CHRIST WATER TECHNOLOGY

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
30.11.2005
On November 8, 2005, the spin-off of CHRIST WATER TECHNOLOGY AG from
BWT Aktiengesellschaft became legally valid by way of its entry in
the commercial register. On the same day, CHRIST shares were floated
on the Prime Market of the Vienna Stock Exchange.
Sales: EUR 129.5 million,  +6.5% y.o.y. In the first nine months of
2005, the CHRIST Group increased its consolidated sales by 6.5% as
against the previous year from EUR 121.5 million to EUR 129.5
million. In the third quarter, sales totaled EUR 42.4 million, up
10.4% on the previous year.
Segment                   1 - 9 / 2005 1 - 9 / 2004 + / - %
Pharma & Life Science     31.867       23.935       +33.1%
Ultrapure Water           54.452       58.629       -7.1%
Food & Beverage           16.165       19.611       -17.6%
Municipal Water Treatment 26.996       19.357       +39.5%
Total                     129.480      121.532      +6.5%
Order book: EUR 133.6 million, + 88.7% y.o.y. Order intake: EUR 173.5
million, +44.5% y.o.y. In the period from January to September,
incoming orders improved from EUR 120.1 million to EUR 173.5 million.
In the third quarter alone, new orders in the amount of EUR 57.1
million were awarded. As of the end of September, Christ's order
books amount to EUR 133.6 million and therefore increased by almost
89%.
EBIT: EUR 1.5 million (PY: -EUR 3.5 million) In the first nine
months, EBIT was turned around from a loss of EUR 3.5 million in the
previous year to a profit of EUR 1.5 million. After the first three
quarters of 2005, earnings before taxes amounted to EUR 0.5 million,
a significant improvement after a loss of EUR 4.4 million in the
previous year. Earnings after taxes improved from a loss of EUR 3.3
million to a profit of EUR 0.4 million.
Equity ratio: 28.6% (PY: 27.6%) As of September 2005, noncurrent
assets increased by EUR 0.9 million as against December 31, 2004 to
EUR 29.0 million as a result of investments in property, plant, and
equipment and additions to goodwill. Long-term assets increased from
EUR 12.3 million to EUR 12.9 million. Short-term assets fell from EUR
104.0 million to EUR 97.3 million, primarily as a result of declines
in other receivables. Despite an intensification of operations, total
assets declined from EUR 144.4 million to EUR 139.3 million. Group
equity (including minorities) remained stable as against December 31,
2004, though the equity ratio improved from 27.6% to 28.6% as a
result of the decline in total assets.
Cash flow from the result: EUR 2.4 million In the first nine months
of 2005, the total cash flow from the result amounted to EUR 2.4
million. As a result of the increase in working capital, cash flow
from operations amounted to EUR 1.1 million as of September 2005.
Cash and cash equivalents were EUR 16.7 million as of September 30,
2005, an increase of EUR 4.8 million as against the end of December
2004. Financial liabilities were reduced by EUR 7.1 million.
The number of employees increased from 796 as of December 31, 2004 to
836 as of September 30, 2005. The rise primarily relates to the
expansion of activities in Asia and the newly consolidated Pharma &
Life Science subsidiary. As a result, staff costs increased from EUR
31.8 million to EUR 33.7 million.
Outlook As a result of earnings development to date and the good
order situation, the Management Board is assuming significantly
higher consolidated sales as against the previous year and positive
earnings for 2005 as a whole. Thus, we have achieved our goal for
this year - that of turning the Company around after two difficult
financial years in 2003 and 2004 - and established a foundation for
sustained positive earnings development in the years to come.
The Pro Forma Interim Group Report can be downloaded from
www.christwater.com.
Company profile:
Water to match your needs - Christ is leading supplier of customised
solutions in process plant construction and in the services sector in
the field of pure and ultrapure water production, drinking water
production and the treatment of wastewater and sewage. Christ employs
about 800 qualified persons at more than 30 locations world-wide.
More information on CHRIST WATER TECHNOLOGY can be downloaded from
www.christwater.com.
end of announcement                               euro adhoc 30.11.2005 08:00:00

Further inquiry note:

CHRIST WATER TECHNOLOGY AG
A-5310 Mondsee, Austria, Walter-Simmer-Strasse 4
Investor Relations
Tel. +43 6232 9011-1001, Fax. +43 6232 9011-1196, E-Mail:
investor.relations@christ-water.com

Branche: Biotechnology
ISIN: AT0000499157
WKN: 675399
Index: WBI, ATX Prime
Börsen: Wiener Börse AG / official market